Key result
Review highlights Torque teno virus DNA load as an immune function marker in transplant recipients.
Supports TTV DNA load as potential immune biomarker in transplant recipients; leaves open prospective validation before clinical adoption.
The main challenge of immunosuppressive therapy after solid organ transplantation is creating an immunological balance that prevents organ rejection without promoting opportunistic infections. Torque teno virus (TTV) is a prevalent, nonpathogenic and ubiquitous DNA virus from the Anelloviridae family in humans.1 Its replicates in the bone marrow, liver, and T lymphocytes.2 Several studies have explored TTV DNA load as a marker of immune function to assess infection and rejection risk in kidney transplant recipients.
No takes yet. Share an insight, caveat, or question.
Truffot et al. (2025) studied Solid organ transplantation. Torque Teno Virus DNA Load measurement in Plasma vs Whole Blood was evaluated. The abstract provides only background information on Torque teno virus DNA load as a marker of immune function in transplant recipients, with no study results reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: